We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Prognostic Values of Platelet Parameters in Gynecological Tumors Patients

By LabMedica International staff writers
Posted on 24 Mar 2020
Print article
Image: The XE-5000 Hematology Analyzer is a high volume analyzer that offers unique clinical parameters to aid in better patient care (Photo courtesy of Sysmex Corporation).
Image: The XE-5000 Hematology Analyzer is a high volume analyzer that offers unique clinical parameters to aid in better patient care (Photo courtesy of Sysmex Corporation).
Gynecologic cancers often involve the uterus, ovaries, cervix, vulva, vagina, fallopian tubes, or the peritoneum. The most common gynecologic cancer in the USA is endometrial cancer, followed by ovarian cancer. Many gynecologic cancers manifest as pelvic masses.

Platelets are small, hematopoietic, and anucleate cells released by bone marrow megakaryocytes in the bloodstream, and were described as the major effectors of several physiological and pathophysiological processes, such as hemostasis, thrombosis, immunological defense mechanisms, and the development of inflammation.

Medical Laboratory Scientists at the Wenzhou Medical University (Wenzhou, China) included in a study a total of 1,062 women who underwent gynecological tumor surgery for the first time between January 2014 and February 2016. Platelet parameters were recorded on the basis of the first complete blood count (CBC) within two weeks before surgery.

Differences of platelet parameters (platelet count [PLT], plateletcrit [PCT], mean platelet volume [MPV], platelet‐large cell rate [P‐LCR], and platelet distribution width [PDW]) between different categories were analyzed by nonparametric test. Venous blood was drawn from patients after admission which would transport to the laboratory within one hour and measured by Sysmex XE5000 hematology analyzer (Sysmex Corporation, Kobe, Japan). All microscopic slides and immunohistochemistry of tissue excised intraoperatively were reviewed by two pathologists. Computed tomography (CT) scan and lymph node metastasis sites were used to detect metastatic status.

The investigators reported that the platelet count and PCT were significantly increased, and MPV and P‐LCR were significantly reduced in malign and benign gynecological tumor groups compared with the controls; PDW had no significant differences. There were no significant differences in PLT, PCT, MPV, P‐LCR, and PDW between different tumor locations and pathologic types. The optimal cutoff values of PLT, PCT, MPV and P‐LCR were 274, 0.26, 10.08, and 24.8 (AUC: 0.661, 0.643, 0.593, 0.562), and PCT had preferable sensibility and specificity (50.8% and 70.4%) in predicting the presence of gynecological tumors. According to survival analysis, increased PLT (≥274 × 109/L) and PCT (≥0.26), and induced MPV (<10.08 fL) and P‐LCR (<24.8%) were associated with shorter overall survival.

The authors concluded that the increased PLT and the decreased platelet volume were not only common in gynecological cancer, but also usual in gynecological benign tumors. PLT, PCT, MPV, and P‐LCR were useful auxiliary parameters for predicting the presence of gynecological tumor. In addition, increased PLT and PCT, or decreased MPV and P‐LCR indicated a heavier tumor burden and shorter overall survival. The study was published on March 13, 2020 in the Journal of Clinical Laboratory Analysis.

Related Links:
Wenzhou Medical University
Sysmex Corporation


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The ePlex system has been rebranded as the cobas eplex system (Photo courtesy of Roche)

Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases

GenMark Diagnostics (Carlsbad, CA, USA), a member of the Roche Group (Basel, Switzerland), has rebranded its ePlex® system as the cobas eplex system. This rebranding under the globally renowned cobas name... Read more

Pathology

view channel
Image: The revolutionary autonomous blood draw technology is witnessing growing demands (Photo courtesy of Vitestro)

Robotic Blood Drawing Device to Revolutionize Sample Collection for Diagnostic Testing

Blood drawing is performed billions of times each year worldwide, playing a critical role in diagnostic procedures. Despite its importance, clinical laboratories are dealing with significant staff shortages,... Read more